View Post

Mature Data Drive New Insights With Novel Agents in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic. The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic, explained Lisa A. Carey, MD, FASCO. …

View Post

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer. Athenex, Inc. held a Type A meeting with the FDA to discuss …

View Post

Naoto Ueno, MD, PhD, on Best Practices for Palliative Care for Patients With Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com “Practical and specific” guide for general oncologists about providing supportive care when specialists are unavailable Palliative care specialists are not always available in everyday practice, and it often falls to general oncologists to assess palliative care needs. Oncologists must therefore be familiar with the requirements and priorities for primary supportive care — a topic recently …

View Post

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Knight Therapeutics From: finance.yahoo.com Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results …

View Post

Positive Topline Survival Data Observed in Phase 3 Trial of SYD985 for HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer. Positive topline results were observed in the phase 3 TULIP study (NCT03262935), which investigated the safety and efficacy of [vic-]trastuzumab duocarmazine (SYD985) compared with physician’s choice of chemotherapy in patients with pretreated …

View Post

Most Women With Metastatic Breast Cancer Have Troubling Treatment Side Effects, Willing To Discuss Dosing Options With Doctor

In In The News by Barbara Jacoby

By: Jamie DePolo From: breastcancer.org About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations, according to a study. The research was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. About …

View Post

Advancing Care in Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Dietmar Berger, Global Head of Development, Sanofi From: onclive.com As the most commonly diagnosed type of cancer, the devastating effects of breast cancer continue to impact families around the world.1 It’s the fifth most frequent cause of cancer deaths globally, resulting in an estimated 685,000 deaths in 2020 alone, and a physical and emotional burden for patients and their …

View Post

Susan G. Komen and Amgen to Help People Understand and Monitor Breast and Bone Health

In In The News by Barbara Jacoby

From: businesswire.com Bone Complication Impacts 70% of People Living with Metastatic Breast Cancer Susan G. Komen®, the world’s leading breast cancer organization, today unveiled a new integrated campaign, in partnership with Amgen, to educate the breast cancer community about the link between breast and bone health, providing useful information for women of all ages and stages of breast cancer. “Breast …

View Post

Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: PR Newswire From: biospace.com Eisai Inc. today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients with metastatic breast cancer (mBC), including the triple-negative breast cancer (TNBC) subtype. These data were recently published in Advances in Therapy. The study was a retrospective, multi-site patient chart …